| Mr Christopher Mcguire, MD | |
|
Kister Ave, Building 5166, U.s. Army Health Clinic, Dugway, UT 84022 | |
| (435) 831-2027 | |
| Not Available |
| Full Name | Mr Christopher Mcguire |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | Kister Ave, Building 5166, Dugway, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093906224 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 44675 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Christopher Mcguire, MD Kister Ave, Building 5166, U.s. Army Health Clinic, Dugway, UT 84022 Ph: (435) 831-2027 | Mr Christopher Mcguire, MD Kister Ave, Building 5166, U.s. Army Health Clinic, Dugway, UT 84022 Ph: (435) 831-2027 |
News Archive
In a recent study, U.S. researchers have reprogrammed cells found in circulating blood into cells that are molecularly and functionally indistinguishable from embryonic stem cells, a revolutionary achievement that provides a readily accessible source of stem cells and an alternative to harvesting embryonic stem cells.
Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.
Cigna today announced that it has come to an agreement with Humana to purchase select Medicare Advantage plans in Texas and Arkansas. The plans in the three markets - Amarillo, Longview-Marshall and Texarkana - are part of a previously announced government-stipulated divestiture for Humana to complete its acquisition of Arcadian Health.
Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.
The lack of protein TDP-43 in two neurodegenerative diseases is shown to prevent neuron growth via failed transport of RNA and subsequent absence of protein synthesis in axons
› Verified 8 days ago
Dr. Susanne Christine Thobe, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: Bldg 5116 Kister Avenue, Dugway, UT 84022 Phone: 435-831-3453 | |
William C Otto, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 629 Coyote Cv, A, Dugway, UT 84022 Phone: 435-831-2222 | |
Ms. Christina Marie Vokt, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 5116 Kister Ave, Dugway, UT 84022 Phone: 801-777-1160 Fax: 801-775-6884 |